Login to Your Account

Other News To Note

Wednesday, December 19, 2012
• Karus Therapeutics Ltd., of Southhampton, UK, entered a collaboration with the Babraham Institute, of Cambridge, UK, to further characterize treatments for inflammatory diseases through the regulation of phosphatidylinositol-3-kinase (PI3K) – a family of enzymes important to immune cell function.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription